P2X7 RECEPTOR TARGETED THERAPY

The invention relates to methods of treating cancer, particular cancers which have developed a resistance to chemotherapeutics. Particularly, the invention relates to a method of treating cancer in an individual who has not responded, or no longer responds, to chemotherapy, the method comprising pro...

Full description

Saved in:
Bibliographic Details
Main Authors LLESHI, Ermira, LARA, Romain, MCNULTY, Shaun, GILBERT, Simon, OLIPHANT, Chris
Format Patent
LanguageEnglish
Published 11.08.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to methods of treating cancer, particular cancers which have developed a resistance to chemotherapeutics. Particularly, the invention relates to a method of treating cancer in an individual who has not responded, or no longer responds, to chemotherapy, the method comprising providing an individual who has not responded, or no longer responds, to a chemotherapeutic agent; providing in the individual a whole antibody or a fragment thereof including a variable domain for binding to a P2X7 receptor that is expressed by the individual; wherein the P2X7 receptor has an impaired response to ATP such that it is unable to form an apoptotic pore under normal physiological conditions, thereby treating cancer in the individual.
Bibliography:Application Number: US202017618849